Heparin-induced thrombocytopenia: a review.
Immune heparin-induced thrombocytopenia (HIT) is a relevant adverse drug reaction consisting in a hypercoagulable state caused by an anticoagulant agent. The incidence is approximately 6.5% in patients receiving unfractionated heparin after orthopedic surgery, and is equal to or lower than 1% in other settings. HIT occurrence is a function of heparin type, duration of heparin administration, patient population, and gender. The pathogenesis is due to an antibody response to the complex heparin/platelet factor 4 in most cases, with secondary activation of platelets and coagulation, and finally increased thrombin generation. Thrombocytopenia, venous or arterial thrombosis, heparin-induced skin necrosis, adrenal hemorrhage, and transient amnesia can characterize the clinical course of HIT. Platelet monitoring in patients receiving heparin is indicated to early detect HIT. A thrombotic event can be the first manifestation of HIT. Laboratory demonstration of heparin-dependent platelet activation confirms the clinical diagnosis; antigenic or functional assays are available. Once HIT is highly likely or confirmed serologically, immediate heparin cessation is mandatory and an alternative therapeutic anticoagulant is needed due to the high risk (or the presence) of thrombotic events. The available nonheparin anticoagulants aim to reduce thrombin generation. Lepirudin, argatroban, and bivalirudin (direct thrombin inhibitors) and danaparoid and fondaparinux (factor Xa inhibitors) represent the current treatment options for HIT. Vitamin K antagonists can be used safely only after a stable platelet count has been obtained.
Girolami
Bruno
B
Department of Medicine, Azienda Ospedaliera di Padova, Padova, Italy. bruno.girolami@sanita.padova.it
Girolami
Antonio
A
D000925:Anticoagulants / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000139:chemically induced / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology / Q000503:physiopathology; D005343:Fibrinolytic Agents / Q000009:adverse effects* / Q000276:immunology; D006493:Heparin / Q000009:adverse effects* / Q000276:immunology; D006801:Humans; D012307:Risk Factors; D012737:Sex Factors; D013921:Thrombocytopenia / Q000139:chemically induced / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology / Q000503:physiopathology
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006493:Heparin